Jinom&Company Obtains Patent Rights for Anticancer Immune-Enhancing Substance

[Asia Economy Reporter Junho Hwang] Genome & Company announced on the 29th that it has acquired a patent related to a new target for anticancer and immune-enhancing purposes. A representative of Genome & Company stated, "This invention concerns the anticancer use of substances that inhibit the activation or expression of Contactin-4 (CNTN-4)" and added, "We plan to apply this to the research and development of new drug target-based immune checkpoint inhibitor candidates."